文献速递妇科

左炔诺孕酮宫内装置治疗早期子宫内膜腺癌的病理完全缓解:随机临床试验

Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial.
PubMed 文献 · Gynecol Oncol · 2021-01-01

本II期随机对照试验纳入165例临床I期FIGO 1级子宫内膜腺癌(EAC)或不典型子宫内膜增生(EHA)且BMI>30 kg/m2的患者,所有患者接受左炔诺孕酮宫内装置(LNG-IUD),并随机分为观察组、二甲双胍组或减重组。6个月时病理完全缓解率在观察组为61%、减重组为67%、二甲双胍组为57%,EHA和EAC的缓解率分别为82%和43%。

要点

  • LNG-IUD治疗6个月后EHA的pCR为82%,EAC为43%。
  • 观察组、减重组、二甲双胍组的pCR分别为61%、67%、57%。
  • 该方案在EAC和EHA患者中显示出鼓舞人心的完全缓解率。

核心结论

  • LNG-IUD治疗6个月在EAC和EHA患者中达到鼓舞人心的完全缓解率,且三个治疗组间结果相似。

研究设计与样本

  • II期随机对照临床试验,纳入165例组织学确诊、临床I期FIGO 1级EAC或EHA患者,BMI>30 kg/m2,MRI示肌层浸润深度<50%,血清CA125≤30 U/mL。

主要发现

  • 6个月时pCR率:观察组61%(95%CI 42%至77%),减重组67%(95%CI 48%至82%),二甲双胍组57%(95%CI 41%至72%)。
  • EHA患者pCR为82%,EAC患者pCR为43%。

关键数值与推荐

  • pCR定义为6个月后无任何EAC或EHA证据。
  • 纳入标准:组织学确诊临床I期FIGO 1级EAC或EHA;BMI>30 kg/m2;MRI示肌层浸润深度<50%;血清CA125≤30 U/mL。

临床怎么用

  • 对于要求保留生育功能或手术高风险的超重早期子宫内膜腺癌及不典型增生患者,LNG-IUD可作为治疗选择,6个月时评估病理完全缓解。
  • 二甲双胍或减重联合LNG-IUD未显示优于单独LNG-IUD的缓解率,但各组缓解率均较可观。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Intrauterine levonorgestrel (LNG-IUD) is used to treat patients with endometrial adenocarcinoma (EAC) and endometrial hyperplasia with atypia (EHA) but limited evidence is available on its effectiveness. The study determined the extent to which LNG-IUD with or without metformin (M) or weight loss (WL) achieves a pathological complete response (pCR) in patients with EAC or EHA. PATIENTS AND METHODS: This phase II randomized controlled clinical trial enrolled patients with histologically confirmed, clinically stage 1 FIGO grade 1 EAC or EHA; a body mass index > 30 kg/m2; a depth of myometrial invasion of less than 50% on MRI; a serum CA125 ≤ 30 U/mL. All patients received LNG-IUD and were randomized to observation (OBS), M (500 mg orally twice daily), or WL (pooled analysis). The primary outcome measure was the proportion of patients developing a pCR (defined as absence of any evidence of EAC or EHA) after 6 months. RESULTS: From December 2012 to October 2019, 165 patients were enrolled and 154 completed the 6-months follow up. Women had a mean age of 53 years, and a mean BMI of 48 kg/m2. Ninety-six patients were diagnosed with EAC (58%) and 69 patients with EHA (42%). Thirty-five participants were randomized to OBS, 36 to WL and 47 to M (10 patients were withdrawn). After 6 months the rate of pCR was 61% (95% CI 42% to 77%) for OBS, 67% (95% CI 48% to 82%) for WL and 57% (95% CI 41% to 72%) for M. Across the three treatment groups, the pCR was 82% and 43% for EHA and EAC, respectively. CONCLUSION: Complete response rates at 6 months were encouraging for patients with EAC and EHA across the three groups. TRIAL REGISTRATION: U.S. National Library of Medicine, NCT01686126.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Janda M, Robledo KP, Gebski V, et al. Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial. Gynecol Oncol. 2021. PMID: 33762086. doi:10.1016/j.ygyno.2021.01.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。